A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status  Mohammad Ebrahim Parsanezhad, M.D., Mina Azmoon, Saeed Alborzi, M.D., Abdoreza Rajaeefard, Afsun Zarei, M.D., Talieh Kazerooni, M.D., Vivian Frank, M.D., Ernst Hienrich Schmidt, M.D.  Fertility and Sterility  Volume 93, Issue 1, Pages 192-198 (January 2010) DOI: 10.1016/j.fertnstert.2008.09.064 Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Pattern of effects of letrozole (group A) and triptorelin (group B) on leiomyoma volume during 12 weeks of treatment. Leiomyoma volume was assessed at baseline and during treatment at weeks 2, 4, 6, and 12 by transvaginal ultrasound. Myoma volume declined significantly in the two groups (P<.05). There are no significant differences between the two groups in myoma decline. Fertility and Sterility 2010 93, 192-198DOI: (10.1016/j.fertnstert.2008.09.064) Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Pattern of effects of letrozole (group A) and triptorelin (group B) on serum E2 levels during 12 weeks of treatment. Estradiol level was assessed at baseline and during treatment at weeks 2, 4, 6, and 12. There was no significant change in serum E2 level at all visits in group A. Group B showed a small rise in the first 2 weeks, then the level declined significantly, with a maximum decrease at week 12. Fertility and Sterility 2010 93, 192-198DOI: (10.1016/j.fertnstert.2008.09.064) Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

Figure 3 Pattern of effects of letrozole (group A) and triptorelin (group B) on serum FSH levels during 12 weeks of treatment. The FSH level was assessed at baseline and during treatment at weeks 2, 4, 6, and 12. There was no significant change in serum FSH level at all visits in group A. Group B showed a small rise in the first 2 weeks, then the level declined significantly, with a maximum decrease at week 12th. Fertility and Sterility 2010 93, 192-198DOI: (10.1016/j.fertnstert.2008.09.064) Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

Figure 4 Pattern of effects of letrozole (group A) and triptorelin (group B) on serum LH levels during 12 weeks of treatment. The LH level was assessed at baseline and during treatment at weeks 2, 4, 6, and 12. There was no significant change in serum LH level at all visits in group A. Group B showed a small rise in the first 2 weeks, then the level declined significantly, with a maximum decrease at week 12. Fertility and Sterility 2010 93, 192-198DOI: (10.1016/j.fertnstert.2008.09.064) Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

Figure 5 Pattern of effects of letrozole (group A) and triptorelin (group B) on serum T levels during 12 weeks of treatment. The T level was assessed at baseline and during treatment at weeks 2, 4, 6, and 12. There was no significant change in the serum testosterone level at all visits in group A. Group B showed a small rise in the first 2 weeks, then the level declined significantly, with a maximum decrease in week 12. Fertility and Sterility 2010 93, 192-198DOI: (10.1016/j.fertnstert.2008.09.064) Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions